期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Measles Virus IgG Avidity Assay for Use in Identification of Measles Vaccine Failures in Tianjin, China 被引量:2
1
作者 DING Ya Xing MAO Nai Ying +4 位作者 ZHANG Yan LEI Yue GAO Zhi Gang XU Wen Bo ZHANG Ying 《Biomedical and Environmental Sciences》 SCIE CAS CSCD 2019年第11期804-811,共8页
Objective To identify measles vaccine failures in Tianjin, China using a measles virus Ig G avidity assay.Methods The China Information System for Disease Control and Prevention(CISDCP) was used to collect information... Objective To identify measles vaccine failures in Tianjin, China using a measles virus Ig G avidity assay.Methods The China Information System for Disease Control and Prevention(CISDCP) was used to collect information about measles cases and blood specimens in Tianjin from 2013 to 2015. Measlesspecific Ig M and Ig G antibodies were detected using Enzyme-Linked Immunosorbent Assay(ELISA).Avidity testing for measles Ig G was performed using a commercial enzyme immunoassay(EIA).Results A total of 284 confirmed measles cases were identified. Of this total, 262(92.25%) were in patients aged ≥ 20 years. High avidity was exhibited in 172(60.56%) cases, while 80(28.17%) cases demonstrated low avidity. High avidity was detected in only 21.43% of cases in patients aged < 1 year.The proportion of high avidity increased with age, and was significantly higher in patients aged 30–39 years at 70.07%(χ~2 = 17.27, P = 0.002). Of the 52 measles cases in patients with a history of vaccinations,41(78.85%) cases showed high avidity, indicating secondary vaccine failures(SVF). In these vaccinations,there was no significant difference(P > 0.05) in clinical severity between high avidity and low avidity cases. However, regardless of vaccination status, clinical severity was significantly lower in high avidity cases(P < 0.001) than in low avidity cases. The percentages of positive measles Ig M results in high avidity and low avidity cases were 66.28% and 91.25%, respectively. Geometric Mean Concentration(GMC) was significantly lower in high avidity cases at 33.73 U/m L, compared to 166.07 U/m L in low avidity cases.Conclusions Low clinical severity and inconclusive Ig M antibody results are more likely in high avidity measles cases. Measles cases were more common in adults. Therefore, a further dose of vaccines should be recommended for 30–39 years in Tianjin. 展开更多
关键词 MEASLES IgG avidity China Primary vaccine failures Secondary vaccine failures
暂未订购
Post-Marketing Surveillance of Adverse Events Following Meningococcal Vaccination-China,2013-2021 被引量:1
2
作者 Yuyang Xu Keli Li +5 位作者 Yan Li Yuan Li Lina Zhang Chunxiang Fan Minrui Ren Zundong Yin 《China CDC weekly》 SCIE CSCD 2024年第50期1325-1330,共6页
What is already known about this topic?From 2010 to 2012,the incidence of adverse vaccine reactions from meningococcal vaccine(MenV)in China ranged from 8.46 to 56.30 per 100,000 doses.What is added by this report?Fro... What is already known about this topic?From 2010 to 2012,the incidence of adverse vaccine reactions from meningococcal vaccine(MenV)in China ranged from 8.46 to 56.30 per 100,000 doses.What is added by this report?From 2013 to 2021,the overall reported rate of adverse events following immunization(AEFI)of five types of market-authorized MenV-containing vaccines in China was 37.87 per 100,000 doses administered,with a reported incidence of adverse vaccine reactions of 37.39 per 100,000 doses.The reported incidence of adverse vaccine reactions was comparable to that from 2010 to 2012 and perceived to be within an acceptable range.Most rare vaccine reactions were allergic rashes,and most of these cases were transient and non-serious.What are the implications for public health practice?In China,the incidence of AEFI was very low,and serious abnormal reactions were extremely rare.We should continue to carry out technical training for vaccinators and on-site treatment capabilities to improve emergency treatment for anaphylactic shock and other serious events and ensure the continued safety of vaccination. 展开更多
关键词 doses VACCINE TREATMENT
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部